These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 33797431

  • 21. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.
    Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, Lemm H, Swyter M, Wegener N, Winkler M, Carter JM, Reith S, Werdan K, Buerke M.
    Crit Care Med; 2007 Dec; 35(12):2732-9. PubMed ID: 17893627
    [Abstract] [Full Text] [Related]

  • 22. Vasopressor Therapy in the Intensive Care Unit.
    Russell JA, Gordon AC, Williams MD, Boyd JH, Walley KR, Kissoon N.
    Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475
    [Abstract] [Full Text] [Related]

  • 23. Adrenergic support in septic shock: a critical review.
    Póvoa P, Carneiro AH.
    Hosp Pract (1995); 2010 Feb; 38(1):62-73. PubMed ID: 20469626
    [Abstract] [Full Text] [Related]

  • 24. A plea for personalization of the hemodynamic management of septic shock.
    De Backer D, Cecconi M, Chew MS, Hajjar L, Monnet X, Ospina-Tascón GA, Ostermann M, Pinsky MR, Vincent JL.
    Crit Care; 2022 Dec 01; 26(1):372. PubMed ID: 36457089
    [Abstract] [Full Text] [Related]

  • 25. Essential lessons in cardiogenic shock: epinephrine versus norepinephrine/dobutamine.
    Krenn L, Delle Karth G.
    Crit Care Med; 2011 Mar 01; 39(3):583-4. PubMed ID: 21330855
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study.
    Levy B, Perez P, Perny J, Thivilier C, Gerard A.
    Crit Care Med; 2011 Mar 01; 39(3):450-5. PubMed ID: 21037469
    [Abstract] [Full Text] [Related]

  • 27. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B.
    N Engl J Med; 2021 Aug 05; 385(6):516-525. PubMed ID: 34347952
    [Abstract] [Full Text] [Related]

  • 28. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
    García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-González P, Muñoz MB.
    Eur J Heart Fail; 2006 Nov 05; 8(7):723-8. PubMed ID: 16492404
    [Abstract] [Full Text] [Related]

  • 29. [Modern drug therapy in cardiovascular intensive care medicine].
    Lemm H, Dietz S, Janusch M, Buerke M.
    Internist (Berl); 2015 Jun 05; 56(6):702, 704-8, 710-2. PubMed ID: 26054838
    [Abstract] [Full Text] [Related]

  • 30. Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock.
    How OJ, Røsner A, Kildal AB, Stenberg TA, Gjessing PF, Hermansen SE, Myrmel T.
    Transl Res; 2010 Nov 05; 156(5):273-81. PubMed ID: 20970750
    [Abstract] [Full Text] [Related]

  • 31. Does donor treatment with inotropes and/or vasopressors impact post-transplant outcomes?
    Blitzer D, Baran DA, Lirette S, Copeland JG, Copeland H.
    Clin Transplant; 2023 Apr 05; 37(4):e14912. PubMed ID: 36650699
    [Abstract] [Full Text] [Related]

  • 32. Hemodynamic support in fluid-refractory pediatric septic shock.
    Ceneviva G, Paschall JA, Maffei F, Carcillo JA.
    Pediatrics; 1998 Aug 05; 102(2):e19. PubMed ID: 9685464
    [Abstract] [Full Text] [Related]

  • 33. Levosimendan in the treatment of cardiogenic shock.
    Buerkem B, Lemm H, Krohe K, Dietz S, Raaz U, Buerke U, Russ M, Schlitt A, Werdan K.
    Minerva Cardioangiol; 2010 Aug 05; 58(4):519-30. PubMed ID: 20938415
    [Abstract] [Full Text] [Related]

  • 34. A global perspective on vasoactive agents in shock.
    Annane D, Ouanes-Besbes L, de Backer D, DU B, Gordon AC, Hernández G, Olsen KM, Osborn TM, Peake S, Russell JA, Cavazzoni SZ.
    Intensive Care Med; 2018 Jun 05; 44(6):833-846. PubMed ID: 29868972
    [Abstract] [Full Text] [Related]

  • 35. Inotropic agents in the treatment of cardiogenic shock.
    Bourdarias JP, Dubourg O, Gueret P, Ferrier A, Bardet J.
    Pharmacol Ther; 1983 Jun 05; 22(1):53-79. PubMed ID: 6361798
    [No Abstract] [Full Text] [Related]

  • 36. Shock - Classification and Pathophysiological Principles of Therapeutics.
    Kislitsina ON, Rich JD, Wilcox JE, Pham DT, Churyla A, Vorovich EB, Ghafourian K, Yancy CW.
    Curr Cardiol Rev; 2019 Jun 05; 15(2):102-113. PubMed ID: 30543176
    [Abstract] [Full Text] [Related]

  • 37. Treatment of shock.
    De Backer D.
    Acta Clin Belg; 2011 Jun 05; 66(6):438-42. PubMed ID: 22338308
    [Abstract] [Full Text] [Related]

  • 38. Treatments targeting inotropy.
    Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristić A, Ruschitzka F, Seferović PM, Skouri H, Zimmermann WH, Mebazaa A.
    Eur Heart J; 2019 Nov 21; 40(44):3626-3644. PubMed ID: 30295807
    [Abstract] [Full Text] [Related]

  • 39. Pharmacologic support in cardiogenic shock.
    Rude RE.
    Adv Shock Res; 1983 Nov 21; 10():35-49. PubMed ID: 6349299
    [Abstract] [Full Text] [Related]

  • 40. Cardiogenic shock.
    Rackley CE, Russell RO, Mantle JA, Rogers WJ.
    Cardiovasc Clin; 1981 Nov 21; 11(3):15-24. PubMed ID: 7214388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.